Title Physician

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

NCT ID : 03538314
Phase : 1
Location : Santa Monica, CA
Dr. O'Day

Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin

NCT ID : 04502888
Phase : 1
Location : Santa Monica, CA
Dr. O'Day

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

NCT ID : 04410445
Phase : 3
Location : Santa Monica, CA
Dr. O'Day

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)

NCT ID : 04303169
Protocol Number : MK-3475-02C
Phase : 1 and 2
Location : Santa Monica, CA
Dr. O'Day

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)

NCT ID : 04305054
Protocol Number : MK-3475-02B
Phase : 1 and 2
Location : Santa Monica, CA
Dr. O'Day

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A)

NCT ID : 04305041
Protocol Number : MK-3475-02A
Phase : 1 and 2
Location : Santa Monica, CA
Dr. O'Day

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

NCT ID : 04382664
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT ID : 04291105
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

NCT ID : 03802123
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT ID : 03170960
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

NCT ID : 03820986
Protocol Number : K7902-003
Phase : 3
Location : Santa Monica, CA
Dr. O'Day

A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

NCT ID : 03978611
Phase : 1/2a
Location : Santa Monica, CA
Dr. O'Day

A Phase I Study of AGEN1181, an Fe-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
Dr. O'Day

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
Location : Santa Monica, CA
Dr. O'Day

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3
Location : Santa Monica, CA
Dr. O'Day

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : 3
Location : Santa Monica, CA
Dr. O'Day